An interventional study of Whey Protein Supplementation and Maltodextrin Placebo Capsules in Obesity & Overweight, Muscle Mass and Strength and Muscle Function, sponsored by University of California, Los Angeles. Recruiting at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-04.
Sponsored by University of California, Los Angeles · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 32 studies in Obesity by University of California, Los Angeles — 4 open to participants now, 5 under way, none of them phase 3. Obesity · University of California, Los Angeles.
Among the 32 studies in Obesity by University of California, Los Angeles, this one is the 16th largest by planned enrollment of the 27 interventional ones that give a count, is the only one that started in 2026, is one of 23 with no phase, and was the 32nd registered.
11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.
Browse Obesity studies →4 of the 32 studies in Obesity by University of California, Los Angeles are open now, in 1 country. Recruiting first, the newest first:
University of California, Los Angeles · Sites in United States
Ages 14–21 · Healthy volunteers
University of California, Los Angeles · Sites in United States
Ages 18+ · Healthy volunteers
University of California, Los Angeles · Sites in United States
Ages 13–30 · Healthy volunteers
By country, each count listing its studies:
Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
32 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 2 · Phase 3 1 · Phase 4 1
First in 2004; this study’s year is marked. 1 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 75 is above the median of 67 across 9,023 interventional studies indexed under Obesity.
Median enrollment 100 across the 27 interventional studies, 22 across the 5 observational. Of the 24 that completed or were terminated, 5 (21%) have results posted.
This tab as a report to print or save as PDF → With an account.
University of California, Los Angeles is the lead sponsor of 1,170 studies on the registry; 194 are open to participants now.
Of its 95 completed or terminated interventional studies of FDA-regulated products, 70 (74%) have results posted.
3 of the studies in Obesity by University of California, Los Angeles that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05530538University of California, Los AngelesBrainWeighve App Feasibility Study | 2026-12 |
| NCT04997473University of California, Los AngelesBehavioral Weight Loss Intervention Utilizing Mobile Health Technology in Hematopoietic Stem Cell Transplant Patients | 2027-01-09 |
| NCT05949008University of California, Los AngelesEffect of Metformin, a Drug Used to Treat Diabetes, vs Placebo | 2027-10-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 32 studies in Obesity by University of California, Los Angeles, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This pilot study will examine whether daily protein supplementation with or without a mixture of culinary spices can help preserve muscle mass and function in adults who are using GLP-1 medications for weight management.
The study will include 75 adults who recently started a GLP-1 medication and are experiencing weight loss. Participants will be randomly assigned to one of three groups: standard of care, protein supplementation plus placebo capsules, or protein supplementation plus mixed spice capsules. The study will last 6 months.
Researchers will compare changes in muscle mass and muscle function among the groups. Muscle mass will be measured using DEXA and D3-creatine enrichment. Muscle function will be assessed using walking, stair-climbing, and grip-strength tests. The study will also evaluate metabolic and inflammatory markers, body composition, dietary intake, physical activity, fatigue, sleep quality, quality of life, and other measures related to muscle health.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will continue their prescribed GLP-1 medication and routine clinical management under the direction of their treating healthcare provider. The study will not determine GLP-1 medication selection, dosing, dose adjustments, or clinical management. Participants will receive standardized dietary/calorie and physical activity guidance and will complete the same study assessments and follow-up visits as participants in the intervention groups. They will not receive the study protein supplement, spice capsules, or placebo capsules.
Participants will receive protein supplementation with a goal of total protein intake of 1.2 g/kg lean body mass per day, based on baseline lean body mass measured by DEXA, plus placebo capsules containing 4 g of maltodextrin daily for 6 months. Participants will also receive standardized dietary/calorie and physical activity guidance.
Dietary Supplement: Whey Protein Supplementation · Dietary Supplement: Maltodextrin Placebo Capsules
Participants will receive protein supplementation with a goal of total protein intake of 1.2 g/kg lean body mass per day, based on baseline lean body mass measured by DEXA, plus 4 g of mixed spice capsules daily for 6 months. The daily spice mixture contains 1.0 g turmeric, 1.5 g cinnamon, 0.5 g oregano, 0.5 g black pepper, 0.3 g sage, and 0.2 g thyme. Participants will also receive standardized dietary/calorie and physical activity guidance.
Dietary Supplement: Whey Protein Supplementation · Dietary Supplement: Mixed Spice Capsules
Participants will receive Nutrasumma 100% Whey Protein Isolate (unflavored), providing 20 g whey protein isolate per serving. The 20 g of protein from the shake will count toward the total daily protein goal of 1.2 g/kg lean body mass/day. The remaining protein target will be met through the participant's usual diet.
Participants will consume placebo capsules containing 4 g of maltodextrin daily for 6 months.
Participants will consume 4 g of mixed spice capsules daily for 6 months. The daily mixture contains 1.0 g turmeric, 1.5 g cinnamon, 0.5 g oregano, 0.5 g black pepper, 0.3 g sage, and 0.2 g thyme.
Change in Muscle Mass Measured by DEXA
Muscle mass will be assessed using dual-energy X-ray absorptiometry (DEXA). Change in muscle mass from baseline to 6 months will be compared among the three study groups.
Time frame: Baseline, 3 months, and 6 months
Change in Muscle Mass Measured by D3-Creatine Enrichment
Muscle mass will be assessed using the D3-creatine (D3Cr) dilution method. Change in muscle mass from baseline to 6 months will be compared among the three study groups. Urinary D3-creatine enrichment will be measured by liquid chromatography with tandem mass spectrometry and used to estimate total body skeletal muscle mass.
Time frame: Baseline and 6 months
Change in 400-Meter Walk Test Performance
Muscle function will be assessed using the 400-meter walk test.
Time frame: Baseline, 1 month, 3 months, and 6 months
Change in Stair Climbing Test Performance
Muscle function will be assessed using a stair climbing test.
Time frame: Baseline, 1 month, 3 months, and 6 months
Change in Grip Strength
Grip strength will be measured using a handheld dynamometer and recorded in kilograms. The best of three trials for each hand will be used in the analysis.
Time frame: Baseline, 1 month, 3 months, and 6 months
Change in Mitochondrial Function
Mitochondrial function will be assessed in peripheral blood mononuclear cells (PBMCs), including autophagy and mitochondrial assays.
Time frame: Baseline, 3 months, and 6 months
Change in Fasting Glucose
Fasting glucose will be measured to assess glucose homeostasis.
Time frame: Baseline, 3 months, and 6 months
Change in Fasting Insulin
Fasting insulin will be measured to assess insulin sensitivity.
Time frame: Time Frame: Baseline to 6 months
Change in C-Peptide
Description: Fasting C-peptide will be measured as a marker of pancreatic beta-cell function.
Time frame: Baseline, 3 months, and 6 months
Change in Glucagon
Description: Fasting glucagon will be measured as a metabolic marker.
Time frame: Baseline, 3 months, and 6 months
Change in Glucose-Dependent Insulinotropic Polypeptide (GIP)
Fasting GIP will be measured to evaluate metabolic pathways related to glucose regulation.
Time frame: Baseline, 3 months, and 6 months
Change in High-Sensitivity C-Reactive Protein (hs-CRP)
Description: High-sensitivity C-reactive protein will be measured as a marker of systemic inflammation.
Time frame: Time Frame: Baseline, 3 months, and 6 months
Change in Body Weight
Time frame: Baseline, 1 month, 3 months, and 6 months
Change in Body Composition by Bioelectrical Impedance Analysis
Body composition will be assessed using an InBody bioelectrical
Time frame: Baseline, 1 month, 3 months, and 6 months
Change in Fatigue Assessed by PROMIS Fatigue Short Form 8a
Fatigue will be assessed using the PROMIS Fatigue Short Form 8-item questionnaire.
Time frame: Baseline, 1 month, 3 months, and 6 months
Change in Quality of Life Assessed by SF-36
Quality of life will be assessed using the 36-Item Short Form Health Survey (SF-36).
Time frame: Baseline, 1 month, 3 months, and 6 months
Change in Sleep Quality Assessed by Pittsburgh Sleep Quality Index (PSQI)
Sleep quality will be assessed using the Pittsburgh Sleep Quality Index (PSQI). The global PSQI score ranges from 0 to 21, with higher scores indicating poorer sleep quality.
Time frame: Baseline, 1 month, 3 months, and 6 months
Change in Dietary Energy and Macronutrient Intake
Dietary energy and macronutrient intake will be assessed using 24-hour dietary recalls.
Time frame: Baseline, 1 month, 3 months, 4.5 months, and 6 months
Change in Physical Activity
Physical activity will be monitored using step counts from participants' personal devices and self-reported physical activity recorded using MyNetDiary.
Time frame: Baseline, 1 month, 3 months, 4.5 months, and 6 months
Change in Gut Microbiome Composition
Gut microbiome composition will be assessed using fecal samples
Time frame: Baseline and 6 months
Started Oct 2026 (actual). Primary completion is estimated for Sep 2028, 22 months after the start.
Of 3,690 non-industry interventional studies with no phase under Obesity, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's planned 22 months is close to that.
Counting every sponsor, half of 3,853 studies reached it within 22 months; a quarter within 9 and three quarters within 42.
Start moved once since we started tracking on Sep 25, 2026: Sep 2026 → Oct 2026, on Nov 4, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of California, Los Angeles →